Clinical Trials

Enrolling Trials

31-40  of  137
AALL1331, Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Manalang, Michelle
Blood - ALL - Acute Lymphocyctic
Child
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Monoclonal antibodies, such as blinatumomab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether standard combination chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia.
Welter, Stacy L
(715) 221-6492
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI  54449
ABTR01B1, A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
McManus, Michael J
Biology
Child
This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help the study of cancer in the future.
Welter, Stacy L
(715) 221-6492
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
ACNS0831, Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
McManus, Michael J
Brain, Spinal Cord - Brain Primary
Child, Adult
This randomized phase III trial is studying maintenance chemotherapy to see how well it works compared to observation following induction chemotherapy and radiation therapy in treating young patients with newly diagnosed ependymoma. Drugs used in chemotherapy, such as vincristine sulfate, carboplatin, cyclophosphamide, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving chemotherapy with radiation therapy may kill more tumor cells and allow doctors to save the part of the body where the cancer started.
Welter, Stacy L
(715) 221-6492
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI  54449
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers
Onitilo, Adedayo A
Lung - Lung
Adult
This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.
Bulgrin, Angela M
(715) 221-7261
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Ladysmith Center
906 College Ave W
Ladysmith, WI  54848
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Marshfield Clinic Cancer Care At St Michaels
900 ILLINOIS AVE
STEVENS POINT, WI  54481
Mfld Clinic Cancer Care at Sacred Heart Hospital
900 W CLAIREMONT AVE
EAU CLAIRE, WI  54701
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI  54868
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
AEWS1221, Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Manalang, Michelle
Soft Tissue, Bone - Soft Tissue Sarcoma
Child
This randomized phase II trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without ganitumab in treating patients with newly diagnosed Ewing sarcoma
Welter, Stacy L
(715) 221-6492
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI  54449
AFT-19, A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Fagbemi, Seth O
Bladder, Prostate, Kidney - Prostate
Adult
This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time = 9 months at the time of study entry.
Hileman, Melissa B
(715) 221-7272
Chippewa Center
2655 CTY HWY I
CHIPPEWA FALLS, WI  54729
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Marshfield Clinic Cancer Center - Eau Claire
2200 Craig Road
Eau Claire, WI  54701
Marshfield Clinic Research Foundation
1000 N Oak
Marshfield, WI  54449
Minocqua Center
9601 TOWNLINE RD
MINOCQUA, WI  54548
Rice Lake Center
1700 W STOUT ST
RICE LAKE, WI  54868
Stevens Point Center
,   
Wausau Center
2727 PLAZA DRIVE
WAUSAU, WI  54401
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
Wisconsin Rapids Center
220 24TH ST SOUTH
WISCONSIN RAPIDS, WI  54494
AHOD1331, A Randomized Phase III Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
Manalang, Michelle
Lymph Gland - Hodgkin's
Child
This randomized phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating younger patients with newly diagnosed Hodgkin lymphoma. Combinations of biological substances in brentuximab vedotin may be able to carry cancer-killing substances directly to Hodgkin lymphoma cells. Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if combination chemotherapy is more effective with or without brentuximab vedotin in treating Hodgkin lymphoma.
Schillinger, Debra D
(715) 387-9521
Welter, Stacy L
(715) 221-6492
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI  54449
ALTE07C1, Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
Manalang, Michelle
Treatment of Side Effects
Child
Neuropsychological and behavioral assessments are a crucial component of monitoring for late effects in patients being treated, normally quite aggressively, for cancer. This is especially true for patients that are exposed to potentially neurotoxic therapies. However, lack of compliance with assessment schedules, variations in assessment schedules and neuropsychological measures utilized across studies, as well as overly complex and long neuropsychological assessments have proved to be problematic to the assessment process within the Children's Oncology Group (COG). In order to remediate these problems, a streamlined and standardized neuropsychological and behavioral assessment battery has been developed. The COG Standard Neuropsychological and Behavioral Battery is a focused assessment of critical functional domains that have been empirically shown to be most affected by childhood cancer, its treatment, or other disease related factors. This battery was designed to provide a brief measure of neuropsychological and behavioral function in order to strike a balance between research goals, the clinical needs of the patient, and time constraints on the institutional neuropsychologist/psychologist. The battery of tests will take only about 1 hour to administer and all patients will be tested at 3 standardized timepoints. Parent-completed questionnaires will also be utilized to gather information about the patient's function, specifically in terms of attention, memory, executive abilities, and behavioral/social/emotional adaptation.
Welter, Stacy L
(715) 221-6492
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI  54449
AMPLATZER PFO Occluder Post Approval Study (PFO PAS)
Shah, Milind S
Cardiology - Other
Adult
The purpose of this research study is to collect additional information on the safety and effectiveness of the commercially approved AMPLATZER PFO Occluder.
Mueller, Arika P
(715) 389-7543
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Weston Center
3501 CRANBERRY BLVD
WESTON, WI  54476
ANBL00B1, Neuroblastoma Biology Studies
Manalang, Michelle
Biology
Child
The objectives of the study are to prospectively analyze the factors that are currently used for risk-group assignment (NDA content by flow cytometry, MYCN copy number by FISH, and tumor histology using the International Neuroblastoma Pathologic Classification System) in neuroblastoma tumors at the time of diagnosis. To maintain a reference bank containing clinical and genetically characterized frozen tumor tissue, tumor DNA and RNA, tumor touch perpetration, histology slides and blocks, cell lines, and paired normal DNA obtained at the time of diagnosis (all patients), at the time of second-look surgery (high-risk patients), and relapse (all patients) for future research studies. To prospectively analyze the prevalence of 1p, 11q, 14q LOH and gain of 17q; the expression of nerve growth factor (NGF) and its high affinity (Trk-A) and low affinity (p75NTR) receptors; and telomerase activity in diagnostic neuroblastoma tumors, and to determine the independent clinical significance of these biologic factors compared to MYCN amplification, INSS stage, age, and histologic variables in predicting either response to treatment or outcome. To build a database of the known biologic prognostic factors for patients on therapeutic studies. Adjustment for, or stratification by, these prognostic factors will be performed when testing for treatment effect in Phase III trials.
Welter, Stacy L
(715) 221-6492
Marshfield Center
1000 N OAK AVE
MARSHFIELD, WI  54449
Marshfield Medical Center
611 Saint Joseph Ave
Marshfield, WI  54449